Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Find insight on Merck KGaA, Bayer, Jazz Pharmaceuticals and the use of AI in China’s healthcare sector in the latest Market ...

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...

No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. Blair, best known for her roles in turn ...

The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...

Just days after announcing sweeping job cuts at NHS England, UK Prime Minister Keir Starmer has said that the government ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company’s goal is to achieve a 50-50 split ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...